Cardiovascular effects of epidurally administered oxymorphone and an oxymorphone-bupivacaine combination in halothane-anesthetized dogs.
OBJECTIVE
To evaluate cardiovascular effects of epidurally administered oxymorphone (OXY) and an OXY-bupivacaine combination (O/B) in halothane-anesthetized dogs.


METHODS
6 dogs.


METHODS
In a randomized crossover design study, dogs were anesthetized with halothane and given OXY, O/B, and saline solution (SAL). Eucapnia and end-tidal halothane concentration of 1.2% were established. Heart rate (HR), systemic and pulmonary arterial pressures, central venous pressure (CVP), and cardiac output were measured at baseline and 5, 15, 30, 45, 60, and 75 minutes after treatment. At 90 minutes, glycopyrrolate was administered IV, and measurements were repeated at 95 minutes. Cardiac index (CI), stroke volume, stroke index, systemic vascular resistance (SVR), and left ventricular work were calculated. End-tidal halothane concentration was decreased to 0.8% from 17 to 45 minutes and to 0.5% from 47 to 95 minutes for OXY and O/B, whereas for SAL, it was maintained at 1.5 and 1.2%, respectively. Samples were obtained at 0, 2, 5, 15, 30, 45, 60, and 95 minutes for measurement of serum opiate concentration and comparison with values after IM administration of OXY.


RESULTS
HR decreased, but CVP and SVR increased in response to OXY and O/B. These changes were reversed after IV administration of glycopyrrolate, resulting in significant increase in CI, compared with that in response to SAL. Serum opiate concentration increased markedly and peaked within 15 minutes after OXY and O/B administration but did not differ from values after IM administration.


CONCLUSIONS
Epidural administration of OXY results in rapid systemic uptake and decreased HR. Glycopyrrolate administration improves HR, resulting in improved CI at equipotent halothane concentrations.
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Canada.
K E
KE
Torske
D H
DH
Dyson
P D
PD
Conlon
D015360:Analgesia, Epidural / Q000662:veterinary; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D019162:Anesthetics, Combined / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D018685:Anesthetics, Inhalation; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001774:Blood Chemical Analysis / Q000662:veterinary; D001794:Blood Pressure; D002045:Bupivacaine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects*; D018592:Cross-Over Studies; D004285:Dogs / Q000502:physiology*; D004569:Electroencephalography / Q000662:veterinary; D005260:Female; D016231:Fluorescence Polarization Immunoassay / Q000662:veterinary; D006024:Glycopyrrolate / Q000494:pharmacology; D006221:Halothane; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D010111:Oxymorphone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D000701:Analgesics, Opioid; D019162:Anesthetics, Combined; D018685:Anesthetics, Inhalation; D000779:Anesthetics, Local; D018727:Muscarinic Antagonists; D010111:Oxymorphone; D006221:Halothane; D006024:Glycopyrrolate; D002045:Bupivacaine